Should I buy or sell Vaxart stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks .

What is Vaxart's stock price target for 2024?

2 analysts have issued 1-year price objectives for Vaxart's shares. Their VXRT share price targets range from $2.00 to $4.00. On average, they predict the company's share price to reach $3.00 in the next year. This suggests a possible upside of 230.1% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts .

How have VXRT shares performed in 2024?

Vaxart's stock was trading at $0.5728 at the beginning of 2024. Since then, VXRT shares have increased by 58.6% and is now trading at $0.9087. View the best growth stocks for 2024 here .

When is Vaxart's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our VXRT earnings forecast .

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) posted its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The biotechnology company had revenue of $3.25 million for the quarter, compared to analysts' expectations of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative trailing twelve-month return on equity of 108.45%.

When did Vaxart's stock split?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) , ADMA Biologics (ADMA) , Novavax (NVAX) , Organigram (OGI) and Novan (NOVN) .

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd , Robert A Yedid, Sean Tucker , W Mark Watson and Wouter Latour . View institutional ownership trends .

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VXRT

Vaxart (VXRT) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free VXRT Stock Alerts

$0.89

-0.02 (-2.56%)

(As of 10:40 AM ET)

Compare

Today's Range: $0.86
▼
$0.91
50-Day Range: $0.91
▼
$1.41
52-Week Range: $0.53
▼
$1.59

Volume: 292,563 shs
Average Volume: 2.00 million shs
Market Capitalization: $154.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get Vaxart alerts:

Vaxart MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 230.1% Upside
$3.00 Price Target
Short Interest: Bearish
9.89% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.45) to ($0.38) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

753rd out of 930 stocks

Biological Products, Except Diagnostic Industry

129th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vaxart has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.89% of the outstanding shares of Vaxart have been sold short.
Short Interest Ratio / Days to Cover
Vaxart has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Vaxart has recently increased by 10.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vaxart does not currently pay a dividend.
Dividend Growth
Vaxart does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VXRT.

3.6

News and Social Media Coverage

News Sentiment
Vaxart has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vaxart this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
5 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxart insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Vaxart is held by insiders.
Percentage Held by Institutions
Only 18.05% of the stock of Vaxart is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vaxart are expected to grow in the coming year, from ($0.45) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxart is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxart is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxart has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Vaxart Stock (NASDAQ:VXRT)

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

VXRT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VXRT Stock News Headlines

April 9, 2024 | investorplace.com

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

March 27, 2024 | globenewswire.com

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 20, 2024 | globenewswire.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2024 | finance.yahoo.com

Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)

March 15, 2024 | finance.yahoo.com

Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript

March 14, 2024 | investorplace.com

VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023

March 14, 2024 | finance.yahoo.com

Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 14, 2024 | globenewswire.com

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

March 7, 2024 | globenewswire.com

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

March 6, 2024 | marketwatch.com

Vaxart Names Steven Lo President, Chief Executive

March 6, 2024 | globenewswire.com

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

February 20, 2024 | finance.yahoo.com

VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?

February 5, 2024 | finance.yahoo.com

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

January 16, 2024 | marketwatch.com

Vaxart CEO Resigns; Biotech Raises $10 Million in Stock Sale

January 16, 2024 | finance.yahoo.com

Vaxart, Inc. Announces Management Change

January 16, 2024 | finance.yahoo.com

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

December 21, 2023 | finance.yahoo.com

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 7, 2023 | finance.yahoo.com

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

November 3, 2023 | finance.yahoo.com

Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates

November 2, 2023 | finance.yahoo.com

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

October 26, 2023 | finance.yahoo.com

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

September 21, 2023 | finance.yahoo.com

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

September 10, 2023 | markets.businessinsider.com

Vaxart (VXRT) Receives a Buy from Cantor Fitzgerald

See More Headlines

Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:VXRT
Previous Symbol: NASDAQ:NABI
CUSIP: N/A
CIK: 72444
Web: www.vaxart.com
Phone: (650) 550-3500
Fax: 650-871-8580
Employees: 109
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $4.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +230.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,460,000.00
Net Margins: -1,117.56%
Pretax Margin: -1,114.03%
Return on Equity: -108.45%
Return on Assets: -73.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.32
Quick Ratio: 3.32

Sales & Book Value

Annual Sales: $7.38 million
Price / Sales: 21.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.38 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 173,862,000
Free Float: 168,646,000
Market Cap: $158.06 million
Optionable: Optionable
Beta: 0.44

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Sean N. Tucker Ph.D. (Age 55)
Senior VP & Chief Scientific Officer
Comp: $481.52k
Dr. James F. Cummings M.D. (Age 57)
Chief Medical Officer
Comp: $526.96k
Mr. Steven Lo (Age 57)
President, CEO & Director
Mr. Phillip Eric Lee (Age 36)
CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Raymond D. Stapleton Jr. (Age 53)
Ph.D., Chief Technology Officer
Mr. Edward B. Berg (Age 59)
Senior VP & General Counsel
Ms. Shaily Jaini Garg
Senior Vice President of Clinical Development & Project Management
Dr. Rajesh Kapoor Ph.D.
Senior Vice President of Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VXRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxart stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings or view top-rated stocks.
What is Vaxart's stock price target for 2024?: 2 analysts have issued 1-year price objectives for Vaxart's shares. Their VXRT share price targets range from $2.00 to $4.00. On average, they predict the company's share price to reach $3.00 in the next year. This suggests a possible upside of 230.1% from the stock's current price.
View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts.
How have VXRT shares performed in 2024?: Vaxart's stock was trading at $0.5728 at the beginning of 2024. Since then, VXRT shares have increased by 58.6% and is now trading at $0.9087.
View the best growth stocks for 2024 here.
When is Vaxart's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VXRT earnings forecast.
How were Vaxart's earnings last quarter?: Vaxart, Inc. (NASDAQ:VXRT) posted its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The biotechnology company had revenue of $3.25 million for the quarter, compared to analysts' expectations of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative trailing twelve-month return on equity of 108.45%.

When did Vaxart's stock split?: Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.
What other stocks do shareholders of Vaxart own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN).
Who are Vaxart's major shareholders?: Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour.
View institutional ownership trends.
How do I buy shares of Vaxart?: Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VXRT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial